News and Trends 4 Oct 2017 Oral Drug to Treat Uterine Fibroids Boasts Phase III Success Myovant’s partner Takeda has reported Phase III results showing relugolix to be more effective in treating uterine fibroids than existing hormonal therapy. Myovant has announced positive results from its lead candidate, relugolix, which showed itself to be better than leuprorelin injections — a common first-line treatment — at reducing menstrual bleeding in a Phase III trial in patients […] October 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2017 CRISPR Gets Snubbed Again by the Nobel Prize Committee The Nobel Prize Committee has made CRISPR wait at least one more year, as it was pipped by research into the mechanisms underlying circadian rhythm. The 2017 Nobel Prize in Physiology or Medicine has been awarded to Jeffrey C. Hall, Michael Rosbash and Michael W. Young. There had been whispers that CRISPR would take home the prize, but the […] October 2, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2017 Belgian Biotech Breaks New Ground in Fight Against Life-Threatening Blood Disorder Ablynx has triumphed where others have fallen by receiving positive Phase III results for the treatment of a dangerous blood disorder with caplacizumab. Ablynx develops nanobodies, molecules with the specificity of antibodies but much smaller in size. Its product, caplacizumab, has received encouraging results for the treatment of the life-threatening autoimmune blood disorder, acquired thrombotic thrombocytopenic purpura (aTTP), which […] October 2, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2017 Drugs Can Now be Delivered to Cells On Demand with Light Cells can be ‘hotwired’ to take up drugs or nanoparticles by endocytosis on demand according to research carried out in the UK. Researchers at Warwick Medical School have found a way to trigger endocytosis in cells. The research, which is published in The Journal of Cell Biology, uses the cell’s own proteins to initiate the endocytosis […] October 2, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2017 Meet the Young CEO of a PCR Workflow Automation Company He is a young entrepreneur with a fast growing company. His software for the automation of PCR results interpretation in research laboratories has had a rocket start. Here’s his story! “I was looking for an internship for my bachelor’s degree in computer science…” His story starts like so many others, but unlike most it took […] October 2, 2017 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2017 Update: The EU Approval of Dupixent Might Bring its Pricing Polemic to Europe Update (01/10/2017): The European Commission has tighter control over pricing that governments have over here Images via Tero Vesalainen, Roman Stetsyk /Shutterstock October 2, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Sep 2017 The Art of Darya Warner: Bacterial Portraits, Meaty Tomatoes and Bioluminescence From beautiful microscopic stills to designing the technology of the future, artist Darya Warner captures the beauty of life in her work. Darya Warner is an artist originally from Belarus, now based in the US, with an eye to spot beauty under the light of the microscope. From genetically engineered fluorescent E. coli to cauliflower, […] September 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2017 Austrian Scientists Turn Human Bone into Surgical Screws An alternative approach for the repair of broken bones is being developed in Austria, which would overcome major limitations of metal surgical screws. Researchers from TU Graz, Austria, are working with the start-up surgebright to develop surgical screws from donated human bone for foot and jaw surgery. Metal screws are the current standard but these have major limitations […] September 29, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2017 French Microbiome Biotech Gets a €6.5M Leg Up to Market Launch LNC Therapeutics is ready to take its oral microbiome-based therapeutic to market for obesity. Investors have contributed a bit of cash to get it there. Bordeaux-based LNC Therapeutics has raked in €6.5M in a Series C. It has raised a total of €16.5M since it was founded in 2010. Seventure Partners, a leading VC focused […] September 28, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2017 German Pharma Enters the Clinic with Solid Tumor Treatment A Phase I study will investigate the safety and tolerability of Immatics approach to treating solid tumors. Immatics is a German biopharma based in Tuebingen, which is a leader in the field of cancer immunotherapy. It has announced today the initiation of a Phase I trial that will test the safety and tolerability of its […] September 28, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2017 Everyone Wants a Piece of this Scottish Biotech’s AI Evotec has doubled down on its investment in Exscientia: the German outfit just announced it has invested €15M to take a minority stake. Sanofi, GSK and Evotec have all jumped at the opportunity to work with Exscientia, a Scottish startup founded in 2012 and incubating in Dundee. Now, Evotec has gone beyond the initial immuno-oncology deal […] September 28, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2017 Oxford Spinout goes for $75M IPO on Nasdaq to Fund Gene Therapy Programs Nightstar has gone public on the American market with the aim of raising $75M for its gene-based retinal disease cures. Spun out from Oxford in 2013, Nightstar is developing and commercializing one-shot gene therapies for various eye diseases that could lead to blindness. This morning, it debuted on the Nasdaq with a projected $75M (£56M / €64M) […] September 28, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email